# Hypersensitivity Reactions: Types and Mechanisms


## Key Takeaways

- Hypersensitivity reactions are maladaptive immune responses causing host tissue damage, classified by Gell and Coombs into four types based on effector mechanisms: Type I (IgE-mediated, rapid onset), Type II (antibody-dependent cytotoxicity), Type III (immune complex deposition), and Type IV (T-cell mediated, delayed onset).
- Type I reactions involve IgE binding to mast cells and basophils, leading to rapid mediator release (histamine, leukotrienes) upon allergen re-exposure, manifesting as anaphylaxis or atopic dermatitis, with diagnosis supported by intradermal testing and allergen-specific IgE assays.
- Type II hypersensitivity involves IgG or IgM antibodies targeting cell surface antigens, leading to complement-mediated lysis, ADCC, or opsonization, exemplified by neonatal isoerythrolysis and immune-mediated hemolytic anemia (IMHA), diagnosed via direct antiglobulin (Coombs) testing.
- Type III reactions are driven by circulating immune complexes depositing in tissues, activating complement and recruiting neutrophils, causing damage via enzymes and reactive oxygen species, seen in serum sickness and glomerulonephritis, often diagnosed by biopsy showing immunoglobulin and complement deposition.
- Type IV hypersensitivity is T-cell mediated, with effector T lymphocytes (CD4+ and CD8+) and macrophages causing delayed-type hypersensitivity or granuloma formation, as in contact dermatitis and tuberculosis, diagnosed by histopathology showing mononuclear infiltrates.
- Clinical presentation and diagnostic approaches vary significantly by species; for instance, horses are prone to Type I insect bite hypersensitivity, while cattle may exhibit Type III reactions to vaccines, necessitating species-specific considerations in diagnosis and management.

---

Hypersensitivity reactions represent the harmful consequences of an adaptive immune response that is excessive, misdirected, or inadequately regulated. These reactions occur when the immune system mounts a response against an antigen in a way that damages host tissues, producing clinical disease that ranges from acute anaphylaxis to chronic granulomatous inflammation. This article provides a cross-species overview of the four Gell and Coombs hypersensitivity types, their underlying immunopathology, and representative veterinary examples. It is written for veterinary students and practitioners who require a mechanistic framework for recognizing and interpreting these reactions in clinical and diagnostic settings.

The classification system described here, originally proposed by Gell and Coombs, remains the standard framework for organizing hypersensitivity reactions by their dominant immune mechanism instead of by clinical presentation alone. Understanding these mechanisms matters because the same clinical sign, such as urticaria or hemolytic anemia, can arise through different pathways with different diagnostic and therapeutic implications. The four types are not mutually exclusive, many diseases involve more than one mechanism simultaneously or sequentially, and a single antigen can elicit different types of hypersensitivity in different individuals or at different stages of disease.

This article focuses on the effector mechanisms, cellular participants, and soluble mediators that define each hypersensitivity type. It deliberately excludes autoimmune diseases as primary entities and does not catalogue specific allergens. Where the evidence base is limited or contested, this is stated explicitly.

## At a Glance

| Parameter | Type I | Type II | Type III | Type IV |
|---|---|---|---|---|
| Immune mediator | IgE, mast cells, basophils | IgG, IgM, complement, ADCC | Immune complexes, complement, neutrophils | Sensitized T lymphocytes, macrophages |
| Time course | Minutes | Hours to days | 4 to 10 hours | 24 to 72 hours or longer |
| Key effector cells | Mast cells, basophils, eosinophils | Phagocytes, NK cells, complement | Neutrophils, macrophages | CD4+ and CD8+ T cells, macrophages |
| Prototypic veterinary example | Anaphylaxis, atopic dermatitis | Neonatal isoerythrolysis, IMHA | Serum sickness, glomerulonephritis | Tuberculosis granuloma, contact dermatitis |
| Diagnostic approach | Intradermal testing, allergen-specific IgE | Direct Coombs test, flow cytometry | Circulating immune complex assays, biopsy | Intradermal delayed-type hypersensitivity testing, histopathology |
| Therapeutic principle | Adrenaline, antihistamines, glucocorticoids | Immunosuppression, supportive care | Remove antigen, anti-inflammatory therapy | Immunosuppression, antigen avoidance |

## The Conceptual Foundation of Hypersensitivity Classification

The Gell and Coombs system classifies hypersensitivity reactions according to the principal immune effector mechanism responsible for tissue damage. This classification is a simplification, but it provides a practical scaffold for differential diagnosis and for understanding why certain therapeutic interventions succeed or fail. Types I through III are mediated by antibodies, whereas type IV is mediated by T lymphocytes. The distinction between antibody-mediated and cell-mediated mechanisms is fundamental because it determines the kinetics of the reaction, the histopathological features, and the likely response to immunomodulatory therapy.

A key conceptual point is that hypersensitivity represents a failure of the normal regulatory mechanisms that limit immune responses. The immune system must distinguish harmful from harmless antigens and must terminate responses once the threat is eliminated. When these controls fail, the same effector mechanisms that provide protective immunity, such as complement activation, neutrophil recruitment, and cytotoxic T cell activity, become sources of tissue injury. This principle is illustrated by the observation that the mechanisms underlying antibody-mediated protection against viral infection have a theoretical potential to amplify infection or trigger harmful immunopathology, a phenomenon known as antibody-dependent enhancement [Arvin et al., perspective on potential antibody-dependent enhancement of SARS-CoV-2](https://pubmed.ncbi.nlm.nih.gov/32659783/).

## Type I Hypersensitivity: Immediate, IgE-Mediated Reactions

### Sensitization and Effector Phase

Type I hypersensitivity begins with sensitization, during which antigen-presenting cells process allergen and present peptides to CD4+ T helper 2 (Th2) cells. These Th2 cells produce interleukin-4 and interleukin-13, which drive B cell class switching to IgE. Allergen-specific IgE binds to high-affinity FcεRI receptors on mast cells and basophils, arming these cells for subsequent exposure. On re-exposure, cross-linking of surface IgE by multivalent allergen triggers degranulation within minutes, releasing preformed mediators including histamine, heparin, and proteases, followed by synthesis of leukotrienes, prostaglandins, and cytokines.

### Clinical Manifestations and Species Variation

The clinical expression of type I hypersensitivity varies markedly by species, route of exposure, and the anatomical distribution of mast cells. In dogs, atopic dermatitis and acute anaphylaxis are common presentations. In cats, the feline eosinophilic granuloma complex and asthma reflect type I mechanisms. Horses develop heaves (equine asthma syndrome) and insect bite hypersensitivity. Cattle and sheep can experience anaphylaxis to vaccines or parasite antigens.

Anaphylaxis represents the most severe systemic form of type I hypersensitivity. The release of large quantities of histamine and other vasoactive mediators produces widespread vasodilation, increased vascular permeability, bronchoconstriction, and cardiovascular collapse. The severity of the reaction depends on the dose of allergen, the route of exposure, and the prior degree of sensitization. The clinical signs differ between species, for example, the gastrointestinal tract is a major target in dogs, whereas the respiratory tract predominates in rabbits and guinea pigs.

## Type II Hypersensitivity: Antibody-Mediated Cytotoxicity

### Mechanisms of Tissue Injury

Type II hypersensitivity occurs when IgG or IgM antibodies bind to antigens on the surface of cells or extracellular matrix components. The bound antibodies then recruit effector mechanisms that destroy the target. Three principal pathways operate: complement-dependent cytotoxicity, in which activation of the classical complement pathway leads to membrane attack complex formation and cell lysis, antibody-dependent cell-mediated cytotoxicity (ADCC), in which NK cells and macrophages recognize bound antibody via Fc receptors and kill the target cell, and opsonisation, in which bound antibody and complement fragments promote phagocytosis.

### Veterinary Examples and Diagnostic Reasoning

Neonatal isoerythrolysis in foals and kittens is a classic type II reaction. A neonate ingests colostral antibodies directed against its own red blood cell antigens, leading to complement-mediated hemolysis. Immune-mediated hemolytic anemia (IMHA) in dogs is another important example, where autoantibodies or drug-induced antibodies target erythrocyte membrane antigens. The direct Coombs test detects antibody or complement on the surface of red blood cells and is a key diagnostic tool.

Type II reactions can also target non-cellular structures. Goodpasture-like syndromes, in which antibodies bind to basement membrane components, and pemphigus complex, where antibodies target desmosomal proteins, are type II mechanisms directed against extracellular antigens. The clinical consequences depend on the target tissue, hemolysis, thrombocytopenia, neutropenia, and blistering skin diseases all fall within this category.

## Type III Hypersensitivity: Immune Complex-Mediated Reactions

### Immune Complex Formation and Deposition

Type III hypersensitivity results from the formation of antigen-antibody complexes that deposit in tissues and trigger inflammation. Under normal conditions, immune complexes are cleared by the mononuclear phagocyte system. When complexes form in antigen excess, when they are large and insoluble, or when the clearance capacity is overwhelmed, they deposit in vascular walls, glomerular basement membranes, and synovial membranes. Deposited complexes activate complement, generating C3a and C5a, which recruit neutrophils. These neutrophils release proteolytic enzymes and reactive oxygen species, producing tissue damage.

### Local and Systemic Patterns

The pattern of disease depends on whether the immune complexes form locally or systemically. The Arthus reaction is a localized form that develops when antigen is injected into a sensitized individual, producing immune complexes at the injection site with edema, hemorrhage, and necrosis within hours. Serum sickness is the systemic form, occurring when large quantities of foreign antigen circulate and form complexes that deposit throughout the body. In veterinary medicine, type III mechanisms contribute to glomerulonephritis, polyarthritis, and vasculitis in various species.

The immunopathology of chronic parasitic infections illustrates how persistent antigen exposure drives ongoing immune complex formation. In schistosomiasis, parasite eggs become lodged in hepatic sinusoids and invoke a fibrotic granulomatous response, with the balance between Th1, Th2, and interleukin-17-secreting lymphocytes determining the severity of liver pathology [Wilson et al., immunopathology of schistosomiasis](https://pubmed.ncbi.nlm.nih.gov/17160074/). This example demonstrates that type III mechanisms often operate alongside type IV responses in chronic infectious disease.

## Clinical Assessment and Diagnostic Approach

The clinical diagnosis of a hypersensitivity reaction begins with pattern recognition. The temporal relationship between exposure and clinical signs provides the first major branch point. Type I reactions develop within minutes to a few hours of exposure. Type II and III reactions typically evolve over hours to days. Type IV reactions are delayed, often appearing 24 to 72 hours after antigen contact, though some forms such as granulomatous inflammation develop over weeks.

The history should establish the inciting agent, the route of exposure, prior episodes, and the duration of clinical signs. For recurrent reactions, a chronological record of each episode, including the interval between exposure and onset, is essential. The physical examination should document the distribution of lesions, the presence of systemic involvement, and any evidence of anaphylaxis such as tachycardia, poor pulse quality, tachypnoea, or altered mentation.

Diagnostic testing is guided by the suspected mechanism. Serum IgE assays and intradermal skin testing support a diagnosis of type I hypersensitivity, but neither test alone confirms clinical disease. A positive test indicates sensitization, not necessarily clinical reactivity. The correlation between test results and clinical signs must be interpreted in the context of the history. For type II reactions, the diagnostic approach centers on hematology, blood typing, and direct antiglobulin (Coombs) testing. For type III reactions, the detection of circulating immune complexes is technically challenging and often unrewarding, the diagnosis is usually based on clinical pattern recognition, biopsy findings, and the demonstration of immunoglobulin and complement deposition in affected tissues. Type IV reactions are confirmed by biopsy showing characteriztic mononuclear infiltrates, with or without granuloma formation.

The table below summarizes the diagnostic approach for each hypersensitivity type.

| Hypersensitivity type | Key diagnostic tools | Typical findings | Common pitfalls |
|---|---|---|---|
| Type I | Intradermal testing, serum allergen-specific IgE | Immediate wheal-and-flare response, elevated allergen-specific IgE | Positive tests without clinical disease, poor correlation for food allergens |
| Type II | Direct antiglobulin test, blood typing, hematology | Spherocytosis, anemia, positive direct antiglobulin test | False negatives with low antibody load, recent transfusion confounds typing |
| Type III | Biopsy with immunofluorescence, serology for antigen | Neutrophilic vasculitis, immunoglobulin and complement deposition | Sampling error, immune complexes cleared before biopsy |
| Type IV | Biopsy, patch testing in some species | Perivascular mononuclear infiltrates, granuloma formation | Deep lesions missed by superficial biopsy, patch testing poorly standardized in veterinary species |

## Monitoring Parameters and Treatment Response

The response to treatment provides diagnostic confirmation and guides ongoing management. For acute type I reactions, the resolution of clinical signs within minutes to hours of epinephrine and antihistamine administration supports the diagnosis. For chronic type I conditions such as atopic dermatitis, the response to glucocorticoids or immunomodulatory agents is slower, and the assessment period should extend over several weeks.

Monitoring parameters differ by reaction type. In type II hemolytic anemia, the packed cell volume, reticulocyte count, and serum bilirubin are tracked serially. A rising reticulocyte count indicates bone marrow regeneration, while persistent anemia with low reticulocytes suggests ongoing destruction or marrow suppression. In type III glomerulonephritis, proteinuria, serum creatinine, and blood pressure are monitored. Worsening proteinuria despite immunosuppressive therapy warrants reassessment of the diagnosis or the treatment protocol. In type IV reactions, the clinical assessment is largely visual and tactile, with serial measurement of lesion size, degree of induration, and the presence of ulceration or necrosis.

The choice of monitoring interval depends on the acuity of the reaction and the drugs used. Patients receiving glucocorticoids require monitoring for polyuria, polydipsia, and signs of iatrogenic hyperadrenocorticism. Patients on ciclosporin require periodic assessment of renal function and blood pressure. The current formulary and label references must be consulted for species-specific monitoring recommendations, as requirements differ between dogs, cats, and production animals.

## Species and Production System Considerations

The clinical expression of hypersensitivity reactions varies substantially across species. Horses are particularly prone to type I reactions, with insect bite hypersensitivity and recurrent airway obstruction representing common presentations. Cattle develop type I reactions to vaccines and antibiotics, and type III reactions manifest as pneumonic pasteurellosis in the context of stress and viral infection. Cats show a lower overall incidence of type I disease but develop eosinophilic granuloma complex lesions that reflect a mixed type I and type IV response.

Production systems alter both the risk of exposure and the feasibility of diagnostic testing. In companion animal practice, intradermal testing and allergen-specific immunotherapy are routine. In food animal practice, the cost of testing and the value of the individual animal often preclude extensive workup, and the diagnosis is made on clinical grounds. Withdrawal periods for anti-inflammatory drugs must be considered in food-producing species, and the choice of treatment may be constrained by the availability of approved products. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address disease surveillance and reporting obligations that may apply when hypersensitivity reactions mimic notifiable conditions, particularly in the context of vaccine-associated adverse events.

## Comparative Table of Hypersensitivity Types

The following table provides a consolidated reference for the four hypersensitivity types, their mechanisms, and representative veterinary examples.

| Feature | Type I | Type II | Type III | Type IV |
|---|---|---|---|---|
| Immune mediator | IgE, mast cells, basophils | IgG, IgM, complement, phagocytes | IgG, IgM immune complexes | T lymphocytes, macrophages |
| Time course | Minutes to hours | Hours to days | 4 to 12 hours | 24 to 72 hours or longer |
| Histopathology | Edema, eosinophils, mast cell degranulation | Cell lysis, phagocytosis, complement deposition | Neutrophilic infiltration, vasculitis | Mononuclear infiltrates, granulomas |
| Veterinary examples | Anaphylaxis, atopic dermatitis, insect bite hypersensitivity | Neonatal isoerythrolysis, immune-mediated hemolytic anemia, transfusion reactions | Serum sickness, glomerulonephritis, polyarteritis nodosa | Contact dermatitis, tuberculosis granulomas, feline eosinophilic granuloma complex |
| Diagnostic confirmation | Intradermal testing, IgE serology | Direct antiglobulin test, blood typing | Biopsy with immunofluorescence | Biopsy, response to glucocorticoids |

## Immunopathology and the Risk of Exacerbation

The distinction between protective immunity and harmful immunopathology is not always clear. Antibody responses that neutralise a pathogen can, under certain conditions, enhance infection or amplify inflammation. This phenomenon, known as antibody-dependent enhancement, has been described for several viruses and represents a theoretical concern for vaccine development. The mechanisms that underlie antibody protection have a theoretical potential to amplify infection or trigger harmful immunopathology, and there are currently no clinical findings or biomarkers that reliably differentiate severe viral infection from immune-enhanced disease. This uncertainty is relevant to veterinary vaccinology, where the balance between protective immunity and adverse reactions must be assessed for each product and population.

Cytokine dysregulation contributes to the pathology of several infectious and inflammatory diseases. In highly pathogenic coronavirus infections, a dysregulated immune response with elevated pro-inflammatory cytokine and chemokine responses can result in acute lung injury and acute respiratory distress syndrome. The recognition that immunopathology, instead of direct viral cytopathology, drives much of the tissue damage has implications for the use of immunomodulatory therapy in affected patients.

Interleukin-17 links T-cell activation to neutrophil mobilization and can contribute to the pathogenesis of inflammatory diseases, including periodontal disease and rheumatoid arthritis. The net effect of interleukin-17 signaling promotes disease development in several contexts, and systemic treatments with anti-interleukin-17 biologics have shown promising results in human clinical trials. The role of this pathway in veterinary inflammatory disease is an area of active investigation.

The regulatory mechanisms that limit excessive inflammation are as important as the effector mechanisms that cause it. In toxoplasmosis, natural and inducible regulatory T cells are recruited to stabilize the immune response and limit immunopathology. Similarly, in schistosomiasis, critical control of T helper cell subsets is necessary to prevent severe liver pathology, and alternatively activated macrophages contribute to both fibrosis and immune regulation. These examples illustrate that the clinical outcome of an immune response depends on the balance between effector and regulatory pathways, a principle that applies across the hypersensitivity spectrum.

## Recognized Complications and Early Detection

The most consequential failure mode in hypersensitivity reactions is the progression from localized inflammation to systemic immunopathology. In Type I reactions, this manifests as anaphylaxis, where widespread mast cell degranulation produces cardiovascular collapse and bronchoconstriction before cutaneous signs are apparent. Early detection depends on recognizing the peracute onset of tachypnoea, weak femoral pulses, and altered mentation in a patient known to have been exposed to an inciting antigen. Serial measurement of packed cell volume and total protein can reveal hemoconcentration, which precedes overt hypotension in many species.

Type III reactions present a different diagnostic challenge because immune complex deposition occurs over hours to days, and the initial signs, such as fever, lethargy, and shifting lameness, are nonspecific. The discriminating feature is the temporal association with a recent infection, drug administration, or vaccination. Serial urinalysis for hematuria and proteinuria, together with serial renal function testing, can detect immune complex glomerulonephritis before azotaemia develops. In production animals, unexplained milk drop or reduced feed intake in a group shortly after a common intervention should prompt investigation for a shared antigen source.

Cytokine storm represents a distinct failure mode in which the regulatory mechanisms that normally limit effector responses are overwhelmed. Highly pathogenic viral infections can trigger massive inflammatory cell infiltration and elevated pro-inflammatory cytokine responses that result in acute lung injury, as described in reviews of pathogenic human coronavirus infections [Channappanavar and Perlman on cytokine storm and immunopathology](https://pubmed.ncbi.nlm.nih.gov/28466096/). The veterinary parallel is most often seen in canine parvovirus enteritis with concurrent sepsis, or in feline infectious peritonitis, where the dysregulated immune response drives the clinical syndrome. Early detection relies on trending inflammatory markers, lactate, and perfusion parameters instead of waiting for overt organ failure.

## Common Errors and Corrective Action

Less experienced clinicians frequently misclassify the hypersensitivity type based on timing alone. A reaction that appears within minutes is not necessarily Type I if the patient has been previously sensitized and the current exposure triggers a Type III response with preformed circulating antibody. The corrective action is to document the precise time course, the route of exposure, and the clinical signs, then map these against the mechanistic framework instead of the reverse.

A second common error is treating the effector phase without addressing the inciting antigen. Corticosteroids will suppress the clinical signs of a Type II hemolytic reaction, but if the offending drug is continued, the destruction of erythrocytes persists and the patient becomes transfusion-dependent. The corrective action is to discontinue all suspect medications and re-evaluate the patient after a washout period before attributing improvement to the therapy itself.

Students often overlook the role of regulatory T cells and alternative macrophage activation in limiting pathology. In schistosomiasis, the balance between Th1, Th2, and IL-17-secreting lymphocytes determines whether the granulomatous response remains contained or produces progressive fibrosis [Wilson et al. on the immunopathology of schistosomiasis](https://pubmed.ncbi.nlm.nih.gov/17160074/). The clinical lesson is that a robust inflammatory response is not inherently pathological, the failure to downregulate that response is what produces chronic tissue injury.

| Observation | Likely Cause | Discriminating Check |
|---|---|---|
| Acute collapse after injection | Type I anaphylaxis | Serial blood pressure, hemoconcentration, response to epinephrine |
| Fever and shifting lameness 3 to 10 days after drug start | Type III immune complex disease | Urinalysis for protein and casts, serum complement levels |
| Persistent anemia despite immunosuppressive therapy | Ongoing antigen exposure | Drug history review, direct Coombs test, reticulocyte count |
| Progressive fibrosis despite apparent clinical stability | Dysregulated Th2 response | Serial organ function testing, imaging for structural change |

## Limitations of Current Evidence

The classification of hypersensitivity into four types remains a useful teaching framework, but it does not capture the full complexity of immune-mediated injury. Many clinical syndromes involve contributions from multiple mechanisms, and the boundaries between types are not always distinct. Antibody-dependent enhancement of viral infection illustrates this problem: the same antibody response that provides neutralising protection can, under certain conditions, amplify infection or trigger harmful immunopathology, and no current assay can reliably distinguish protective from detrimental antibody responses [Arvin et al. on antibody-dependent enhancement of SARS-CoV-2](https://pubmed.ncbi.nlm.nih.gov/32659783/).

Expert opinion differs on the value of intradermal testing and allergen-specific serology in the diagnosis of Type I hypersensitivity. Some clinicians prefer intradermal testing for its direct assessment of mast cell sensitization, while others favour serology for its convenience and lack of interference from concurrent antihistamine use. Neither approach is uniformly superior, and the choice depends on the species, the suspected allergen, and the clinical context. The evidence base for immunotherapy dosing protocols is similarly limited, with considerable variation between published regimens.

## Referral, Consultation, and Reporting

Referral is warranted when the diagnosis is uncertain after initial investigation, when the patient fails to respond to first-line therapy, or when the reaction involves organs whose dysfunction carries a poor prognosis, such as the kidney, lung, or myocardium. Specialist consultation with a veterinary immunologist or dermatologist is appropriate for patients requiring allergen identification and immunotherapy, and for those with suspected multiple drug hypersensitivity.

Laboratory involvement extends beyond routine hematology and biochemistry. Flow cytometry for lymphocyte phenotyping, complement assays, and direct immunofluorescence on biopsy specimens can clarify the mechanism of injury when the clinical picture is ambiguous. The [Davis-Thompson Foundation veterinary pathology resources](https://www.davisthompsonfoundation.org/) provide case material and diagnostic teaching resources that support interpretation of biopsy findings.

Regulatory reporting obligations arise when a hypersensitivity reaction is attributable to a licensed veterinary product. Suspected adverse drug reactions should be reported to the relevant national pharmacovigilance scheme, and the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address reporting obligations for notifiable diseases that may present with immune-mediated signs. The [AVMA practice resources](https://www.avma.org/resources-tools) offer guidance on adverse event reporting procedures in the United States, but veterinarians should confirm the specific requirements of their own jurisdiction.

## Frequently Asked Questions

### How Do I Distinguish Between Type I and Type IV Reactions When Presenting With Similar Skin Lesions?

Timing and history are the primary discriminators. Type I reactions develop within minutes to a few hours after exposure, whereas type IV reactions typically peak at 24 to 72 hours. Intradermal testing can help separate the two: immediate wheal-and-flare responses indicate IgE-mediated mast cell degranulation, while delayed induration at the same site suggests T-cell-mediated inflammation. Biopsy findings also differ. Type I lesions show edema and mast cell degranulation with eosinophils, while type IV lesions show perivascular lymphocytic infiltrates. When in doubt, challenge testing under controlled conditions, with appropriate emergency precautions, can confirm the temporal pattern. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific guidance on intradermal testing protocols and interpretation.

### What Should I Do When a Patient Presents With Suspected Anaphylaxis but the Inciting Agent Is Unknown?

Stabilization takes priority over diagnosis. Administer oxygen, intravenous fluids, and epinephrine according to current emergency protocols, then address airway compromise and cardiovascular support. Once the patient is stable, obtain a detailed history covering recent vaccinations, medications, insect stings, and dietary changes. Serum tryptase measurement, where available, can support a diagnosis of anaphylaxis if sampled within a few hours of the event, though normal values do not exclude it. Referral to a dermatology or internal medicine service may be appropriate for allergen identification through skin testing or allergen-specific IgE assays. Document the clinical signs, temporal sequence, and all administered treatments in the medical record, as this information guides future avoidance strategies.

### How Does Hypersensitivity Present Differently in Food Animals Compared With Companion Animals?

Production species often present with herd-level instead of individual patterns. Type I reactions in cattle, for example, may manifest as acute respiratory distress following vaccination, while type III reactions can produce systemic signs such as fever, arthritis, and vasculitis days after exposure. Diagnosis relies on herd history, necropsy findings, and elimination of infectious causes. Regulatory considerations also differ. Reporting requirements for adverse reactions to veterinary products vary by jurisdiction, and the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) outline surveillance expectations for notifiable conditions. Economic factors influence diagnostic workup in production settings, so a cost-effective approach often begins with necropsy of representative affected animals instead of extensive antemortem testing.

### What Are the Practical Limitations of Intradermal Testing in Practice Settings?

Intradermal testing requires experience, appropriate allergen panels, and the ability to interpret subtle reactions. Sedation can interfere with wheal formation, so testing is best performed in cooperative patients or with protocols that account for drug effects. Antihistamines and corticosteroids must be withdrawn for defined periods before testing, which may be impractical in severely affected animals. Regional availability of allergen extracts varies, and panels developed for one geographic area may not reflect local exposures. When intradermal testing is unavailable, serum allergen-specific IgE testing offers an alternative, though results correlate imperfectly with clinical disease. The [Davis-Thompson Foundation veterinary pathology resources](https://www.davisthompsonfoundation.org/) include case material that illustrates typical and atypical presentations, which can support pattern recognition when diagnostic testing is limited.

### How Should I Document Hypersensitivity Reactions in the Medical Record?

Record the suspected trigger, the time between exposure and onset, the clinical signs observed, and the treatment administered. Include photographs where possible, as they provide objective documentation of lesion distribution and severity. Note any prior reactions and whether the current episode differs in character or intensity. For vaccine-associated reactions, record the vaccine brand, lot number, and route of administration. This information supports pharmacovigilance reporting where required. The [AVMA practice resources](https://www.avma.org/resources-tools) offer guidance on adverse event reporting expectations in the United States. Clear documentation also protects against future liability and informs decisions about premedication protocols or avoidance strategies for subsequent exposures.

### How Do I Explain a Hypersensitivity Diagnosis to a Client Without Causing Unnecessary Alarm?

Use analogies that convey the mechanism without oversimplifying. Explain that the immune system sometimes overreacts to a harmless substance, much like a smoke detector that sounds when toast is burned. Distinguish between the acute reaction and the underlying predisposition, and emphasize that many reactions are manageable with avoidance or treatment. Be honest about uncertainty, particularly when the specific trigger has not been identified. Provide written instructions that describe the clinical signs to monitor and the circumstances under which emergency care is needed. Reassure the client that hypersensitivity is common across species and that veterinary professionals have established protocols for managing these conditions, referencing the [MSD Veterinary Manual](https://www.msdvetmanual.com/) as a resource for further reading.

## Related Clinical & Scientific Guides

* [Therapeutic Decision-Making for Respiratory Infections in Cattle](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/therapeutic-decision-making-respiratory-infections-cattle)
* [Monitoring Fluid Therapy in Critically Ill Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-fluid-therapy-critically-ill-veterinary)
* [Monitoring Sedation and Anesthesia Recovery in Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-sedation-anesthesia-recovery-veterinary)


## References and Further Reading

- [A perspective on potential antibody-dependent enhancement of SARS-CoV-2.](https://pubmed.ncbi.nlm.nih.gov/32659783/). 2020.
- [Immune response and immunopathology during toxoplasmosis.](https://pubmed.ncbi.nlm.nih.gov/22955326/). 2012.
- [Acute anterior uveitis and HLA-B27.](https://pubmed.ncbi.nlm.nih.gov/15967191/). 2005.
- [Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.](https://pubmed.ncbi.nlm.nih.gov/28466096/). 2017.
- [Basic biology and role of interleukin-17 in immunity and inflammation.](https://pubmed.ncbi.nlm.nih.gov/26252407/). 2015.
- [Immunopathology of schistosomiasis.](https://pubmed.ncbi.nlm.nih.gov/17160074/). 2007.
- [Davis-Thompson Foundation Veterinary Pathology Resources](https://www.davisthompsonfoundation.org/). Davis-Thompson Foundation.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.
- [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association.

## Related Articles

- [Genetic Diseases in Animals: Mechanisms and Examples](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/genetic-diseases-in-animals-mechanisms-and-examples)
- [Vaccinology: Principles and Vaccine Types](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/vaccinology-principles-and-vaccine-types)
- [Autoimmunity: Mechanisms and Veterinary Examples](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/autoimmunity-mechanisms-and-veterinary-examples)
- [Edema and Shock: Pathophysiologic Mechanisms](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/edema-and-shock-pathophysiologic-mechanisms)
- [Zoonotic Diseases: Mechanisms and Veterinary Public Health](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/zoonotic-diseases-mechanisms-and-veterinary-public-health)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.